Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.

[1]  G. Pond,et al.  A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma , 2014, BJU international.

[2]  P. Albers,et al.  Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. , 2014, Clinical genitourinary cancer.

[3]  G. Pond,et al.  Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy. , 2014 .

[4]  G. Pond,et al.  Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy. , 2014 .

[5]  G. Pond,et al.  Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. , 2013, Clinical genitourinary cancer.

[6]  T. Choueiri,et al.  The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine , 2013, British Journal of Cancer.

[7]  G. Sonpavde,et al.  Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin‐based chemotherapy , 2013, Cancer.

[8]  A. Eisen,et al.  Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. , 2013, The Lancet. Oncology.

[9]  T. Powles,et al.  Treatment patterns and outcomes in “real world” patients (pts) with metastatic urothelial cancer (UC). , 2013 .

[10]  G. Pond,et al.  Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. , 2013, European urology.

[11]  E. Plimack,et al.  Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Schwartz,et al.  Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. , 2012, The Lancet. Oncology.

[13]  R. Sylvester,et al.  Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Kantoff,et al.  Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Sylvester,et al.  Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Sonpavde,et al.  Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. , 2010, The Lancet. Oncology.

[17]  S. Culine,et al.  Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Culine,et al.  Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Albers,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.